Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Antiidiotypic antibody vaccine in murine Schistosomiasis mansoni comprising the internal image of antigen.
T F Kresina, G R Olds
T F Kresina, G R Olds
View: Text | PDF
Research Article

Antiidiotypic antibody vaccine in murine Schistosomiasis mansoni comprising the internal image of antigen.

  • Text
  • PDF
Abstract

This study presents the characterization of an experimental immunotherapeutic approach for schistosomiasis utilizing antiidiotypic antibodies. Antiidiotype (31-3B6) was generated in rabbits using a protective murine monoclonal antibody 31-3B6 which recognizes a 68,000-D molecular mass glycoprotein present in extracts of Schistosomiasis mansoni adult worm homogenetics. Immunization of mice with antiidiotype (31-3B6) before S. mansoni cercariae infection resulted in protection levels ranging from 16 to 41% depending on the route of administration of antiidiotypic antibody and the use of adjuvant. Levels of protection as high as 25% could be obtained with a single injection of antiidiotype (31-3B6) without the use of adjuvant. Animals noted to be resistant to infection with S. mansoni cercariae were also noted to exhibit a humoral immune response that bound components of S. mansoni adult worm homogenetics. This induced antiantigen immune response was shown to bind to the surface of S. mansoni schistosoma by indirect immunofluorescence. Further characterization of the induced antiantigen response showed that a portion (3-32%) of the induced humoral immune response portrayed the binding specificities of the murine monoclonal antibody 31-3B6. The data indicate that antiidiotype antibodies generated utilizing defined monoclonal antibodies can act as surrogate antigens in the protection of infection in schistosomiasis.

Authors

T F Kresina, G R Olds

×

Loading citation information...
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts